Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BOK
REST API REST API
Homo sapiens
BOK is differentially expressed in 129 experiments: 79 organism parts: liver, skeletal muscle, ... (77 more);, 80 disease states: normal, healthy, ... (78 more);, 51 cell types 317 cell lines 14 compound treatments and 40 other conditions.
Synonyms BCL2L9, BOKL, MGC4631
Orthologs ENSCING00000009750 (Ciona intestinalis)   boka (Danio rerio)   A6H6W7_BOVIN (Bos taurus)   bokb (Danio rerio)   Bok (Mus musculus)   Bok (Rattus norvegicus)   BOK (Gallus gallus)   ENSCING00000007880 (Ciona intestinalis)   debcl (Drosophila melanogaster)   Buffy (Drosophila melanogaster)   LOC100491111 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, cytoplasm, cell proliferation, activation of caspase activity, male gonad development, positive regulation of apoptosis, induction of apoptosis, protein dimerization activity, nucleus, protein heterodimerization activity, mitochondrial membrane, brain development, mitochondrion, regulation of apoptosis, oligodendrocyte differentiation, BH domain binding, signal transduction by p53 class mediator resulting in induction of apoptosis
InterPro Term Bcl2_BH, Bcl2-like_apoptosis
UniProt Accession Q9UMX3, Q53NU8, Q53QM7
Search EB-eye ENSG00000176720
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-GEOD-7224, ... (15 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22560, E-GEOD-19639, E-GEOD-24147, E-GEOD-4219, ... (16 experiments)

Factor Value U/D Experiments
K562
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-19639
SG231
1
E-GEOD-22560
MKN74
1
E-GEOD-15460
human foreskin fibroblast
1
E-GEOD-4219
SKLMS1
1
E-MTAB-37
311 more value(s).


Cell type

studied in E-GEOD-15893, E-GEOD-18811, E-AFMX-5, E-MEXP-2488, E-GEOD-20193, ... (22 experiments)

Factor Value U/D Experiments
naive T cell
1
E-GEOD-1460
spheroid recovery
1
E-GEOD-4219
spermatid
1
E-TABM-130
vascular smooth muscle cell
1
E-TABM-130
resting natural killer cell
1
E-TABM-702
wild_type
1
E-GEOD-20193
45 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2508, E-GEOD-15960, E-GEOD-22148, E-GEOD-16363, ... (25 experiments)

Factor Value U/D Experiments
poliovirus-infected
1
E-MEXP-1072
dysferlin mutation
1
E-GEOD-3307
anaplastic lung carcinoma
1
E-MTAB-37
colorectal carcinoma
1
E-GEOD-23878
subependymal giant cell astrocytoma
1
E-MEXP-2351
mesothelioma
1
E-MTAB-37
74 more value(s).


Compound treatment

studied in E-GEOD-20719, E-GEOD-15205, E-GEOD-5741, E-GEOD-6400, E-GEOD-7307, ... (8 experiments)

Factor Value U/D Experiments
actinomycin D
1
E-GEOD-6400
TGF
1
E-GEOD-15205
unknown
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
LDL
1
E-GEOD-5741
estradiol
1
E-GEOD-20081
8 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-6236, E-GEOD-4667

Disease staging
studied in E-GEOD-22544, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-TABM-868, E-TABM-601, E-GEOD-17347 ... (5 experiments)

Growth condition
studied in E-GEOD-13073, E-GEOD-9764, E-GEOD-10315, E-MEXP-1103, E-TABM-440 ... (5 experiments)

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-GEOD-19330, E-TABM-666, E-GEOD-19519, E-TABM-26, ... (15 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Lymph node status
studied in E-GEOD-6532

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-17636, E-GEOD-4600

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19246

RNAi
studied in E-MEXP-1857, E-MEXP-2759

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246

Processing time: 0.43 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM